Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes
Stage III locally advanced non-small cell lung cancer (LA NSCLC) comprises the most heterogeneous group of patients, accounts for one-third of patients with lung cancer, and is unresectable at presentation. Multiple treatment approaches have evolved over the past few decades focusing on timing of chemoradiation (concurrent vs. sequential) and sequencing of therapy (induction vs. consolidation). Concurrent chemoradiation (CCRT) emerged as the standard of care for the majority of the patients worldwide. Despite improvements in median and overall survival (OS) using the concurrent approach, the rate of distant failure remains high. Consolidation with chemotherapy or targeted agents, adding more radiation dose, or induction chemotherapy did not improve OS. With continued research on defining optimal radiation doses and schedules and integrating novel systemic agents, immunotherapy consolidation has renewed optimism. Synergistic use of radiation and immunotherapy can prevent micrometastatic disease and reduce local failure and may have an abscopal effect in addition to survival benefits. The PACIFIC study reported an absolute progression-free survival benefit of 11.2 months with durvalumab consolidation after standard CCRT compared with placebo. The OS data with durvalumab consolidation are encouraging. Durvalumab is the only approved immunotherapy for unresectable stage III LA NSCLC. Improved survival confirms the definitive role of durvalumab as an effective adjuvant therapy after CCRT with no new safety signals. However, the potential mechanisms driving interaction between immunotherapy and chemoradiotherapy require definitive investigation. These mechanisms may help define the timing of immunotherapy initiation as neoadjuvant, adjuvant, or consolidation and maintenance therapy after progression.
AstraZeneca Pharma India Limited.
KeywordsDurvalumab Immunotherapy Stage III LA NSCLC Survival benefit Unresectable
The preparation of this article and funding of the journal’s article processing charges were supported by AstraZeneca Pharma India Limited. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Medical Writing Assistance
The authors thank AstraZeneca Pharma India Ltd and Chinmayee Joshi from Sciformix Technologies Private Limited, Mumbai for providing medical writing assistance in the development of this manuscript.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Senthil Rajappa, Sanjiv Sharma, and Krishna Prasad declare that they have no conflict of interest.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
- 1.Ferlay J, Bray F, Pisani P, Parkin DM. IARC cancer base no 5. Version 2.0. Lyon: IARC Press; 2004. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide.Google Scholar
- 10.Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.Google Scholar
- 14.Aupérin A, Le Péchoux C, Pignon JP, et al. Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17:473–83.CrossRefGoogle Scholar
- 16.Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910–7.CrossRefGoogle Scholar
- 24.Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–99.CrossRefGoogle Scholar
- 28.Calikusua Z, Pelin A. Treatment of locally advanced, unresectable or medically inoperable stage III non-small-cell lung cancer; the past, present and future of chemoradiotherapy. J Oncol Sci. 2018;4:49e52.Google Scholar
- 30.Flentje M, Huber RM, Engel-Riedel W, et al. GILT—a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192:216–22.CrossRefGoogle Scholar
- 31.Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol. 2008;26:5755–60.CrossRefGoogle Scholar
- 33.Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953–62.CrossRefGoogle Scholar
- 36.Kim S, Kim M, Choi E, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial. J Clin Oncol. 2007;25:7528.Google Scholar
- 37.Van Houtte P. Adjuvant or induction chemotherapy for non small cell lung cancer treated with chemoradiotherapy: an individual data metaanalysis of phase II trials [Abstract]. WCLC2013 IASLC. P2:24 021.Google Scholar
- 39.Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28:3739–45.CrossRefGoogle Scholar
- 44.The National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 20 July 2018.
- 50.Clinical trial data. https://clinicaltrials.gov/ct2/show/NCT02343952?cond=pembrolizumab&draw=2&rank=7. Accessed 13 July 2018.
- 51.FDA press announcement February 16, 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm597217.htm. Accessed 13 July 2018.
- 57.Hui R, Ozguroğlu M, Daniel D, et al. Patient-reported outcomes with durvalumab after chemoradiation in locally advanced unresectable NSCLC: data from PACIFIC. In: Presented at the IASLC 18th world conference on lung cancer; October 15–18, 2017, Yokohama. Abstract PL 02.02.Google Scholar
- 58.Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350.Google Scholar
- 59.AstraZeneca Pharmaceuticals LP. Imfinzi receives positive EU CHMP opinion for locally-advanced, unresectable non-small cell lung cancer [press release]. https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-receives-positive-eu-chmp-opinion-for-locally-advanced-unresectable-non-small-cell-lung-cancer-27072018.html. Published 27 July 2018. Accessed 24 Sept 2018.